1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Drugs In Development, 2022, provides an overview of the Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Methicillin-Susceptible Staphylococcus aureus (MSSA) is a bacterium that is resistant to many antibiotics. MSSA usually cause skin infections, but can also cause pneumonia, and other serious types of infections. Symptoms include cellulitis, painful rashes, nausea and vomiting, fever, muscle aches, diarrhea and abdominal pain. Predisposing factors include weakened immune systems, burns and surgical wounds.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 1, 4, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Overview
- Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Companies Involved in Therapeutics Development
- Basilea Pharmaceutica Ltd
- BioPlx Microbiomics Pvt Ltd
- Debiopharm International SA
- Destiny Pharma Plc
- HyPharm GmbH
- LegoChem Biosciences Inc
- Naicons Srl
- Pharma Holdings AS
- Prokaryotics Inc
- Sichuan Saizhuo Pharmaceutical Co Ltd
- Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Drug Profiles
- Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Dormant Projects
- Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Discontinued Products
- Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Product Development Milestones
- Featured News & Press Releases
- Apr 20, 2018: Basilea reports presentations of ceftobiprole data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
- Apr 12, 2018: Cardiome Presents Zevtera Abstracts at ECCMID 2018
- Mar 22, 2018: Sichuan Saizhuo Pharmaceutical obtained the clinical approval for a new drug 'Ristazolone Dry Suspension'
- Apr 21, 2017: Basilea announces agreement with FDA on Special Protocol Assessments for antibiotic ceftobiprole phase 3 clinical studies in bloodstream and skin infections
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Basilea Pharmaceutica Ltd, 2022
- Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by BioPlx Microbiomics Pvt Ltd, 2022
- Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Debiopharm International SA, 2022
- Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Destiny Pharma Plc, 2022
- Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by HyPharm GmbH, 2022
- Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by LegoChem Biosciences Inc, 2022
- Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Naicons Srl, 2022
- Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Pharma Holdings AS, 2022
- Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Prokaryotics Inc, 2022
- Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Sichuan Saizhuo Pharmaceutical Co Ltd, 2022
- Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Dormant Projects, 2022
- Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Discontinued Products, 2022
- Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Basilea Pharmaceutica Ltd
- BioPlx Microbiomics Pvt Ltd
- Debiopharm International SA
- Destiny Pharma Plc
- HyPharm GmbH
- LegoChem Biosciences Inc
- Naicons Srl
- Pharma Holdings AS
- Prokaryotics Inc
- Sichuan Saizhuo Pharmaceutical Co Ltd
